Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
暂无分享,去创建一个
T. Kipps | J. Burger | A. Tedeschi | T. Robak | O. Bairey | J. Dean | S. Coutre | F. Offner | P. Ghia | C. Owen | S. Devereux | P. Barr | P. Hillmen | H. McCarthy | S. Grosicki | I. Lal | D. Simpson | C. Moreno | S. Dai